Relmada Therapeutics, Inc. (RLMD)
7.00
-0.18
(-2.51%)
USD |
NASDAQ |
Apr 16, 16:00
6.995
0.00 (0.00%)
After-Hours: 20:00
Relmada Therapeutics Research and Development Expense (Quarterly) : 8.072M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Catalyst Pharmaceuticals, Inc. | 1.807M |
| Theravance Biopharma, Inc. | 6.963M |
| Avalo Therapeutics, Inc. | 13.27M |
| AN2 Therapeutics, Inc. | 6.879M |
| ACADIA Pharmaceuticals, Inc. | 84.76M |